The First Evaluation of a Novel Vitamin K Antagonist, Tecarfarin (ATI-5923), in Patients With Atrial Fibrillation

200985 citationsJournal Article

Authors

Mohammed Haris Usman · Mercy Catholic Medical Center

Peter G. Milner · Catholic Medical Center

Daniel M. Canafax · Catholic Medical Center

Michael D. Ezekowitz · Catholic Medical Center

Abstract

This is the first study of tecarfarin in patients with atrial fibrillation. It appears that tecarfarin may possess advantages over the currently available standard of care, warfarin, by improving time in therapeutic range. Adequately powered prospective trials are warranted to definitively compare tecarfarin with warfarin in clinical settings for which warfarin is indicated.

Topics & Keywords

Pharmacogenetics and Drug Metabolism Atrial Fibrillation Management and Outcomes Vitamin K Research Studies

Publication Details

Published in: Circulation

Volume 120, Issue 12, pp. 1029-1035

DOI: 10.1161/circulationaha.109.856120

Field-Weighted Citation Impact: 18.49

Command Palette

The First Evaluation of a Novel Vitamin K Antagonist, Tecarfarin (ATI-5923), in Patients With Atrial Fibrillation

Authors

Abstract

Topics & Keywords

Publication Details